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Idiopathic endolymphatic hydrops, often referred as 
Ménière’s disease (MD) is characterized by episodes of 
vertigo, hearing loss, tinnitus, and aural fullness (1,2). It 
is often a challenge in diagnosis and description, mostly 
because of its variability, which can make it difficult to 
recognize, thus possibly delaying treatment (3). Hearing 
loss has been widely studied, a fact that inclusively supports 
its staging according to the different guidelines proposed (4). 
Vertigo attacks appear to be the factor that affects more 
the health related quality of life of these patients as such, 
the primary goal of treatment is to reduce the frequency, 
intensity and duration of these episodes (1,5).
There are several difficulties, any author must stand, 
when analyzing results obtained with any MD treatment 
proposed. Fluctuation nature of the disease, the high and 
unexpected spontaneous remission rate, the difficulty 
of including a control group of patients without any 
intervention and the lack of validated instruments related 
to vertigo outcomes (other than disability and quality of life 
measurements) are clear examples of such problems. Here 
lies the importance of an appropriate clinical trial design, in 
order to prevent those possible methodological errors.
The study here reviewed (6) comprise a multicentre, 
double blind, placebo controlled, three arm trial in 14 
tertiary referral centers to analyze the efficacy of betahistine 
(BH) treatment in MD patients. So far, there are very few 
evidence-based studies available in the medical literature, 
and these kind of high quality trials are essential. For 
instance, in 2000, the Cochrane Ear, Nose and Throat 
Disorders group evaluated the efficacy of BH on MD 
patients: only six clinical trials met the criteria to be 
included in the meta-analysis not being possible to reach 
any objective result, due to the extreme heterogeneous 
methodology between the different included studies. 
Similar problems were encountered when the Cochrane 
Ear, Nose and Throat Disorders group evaluated the effect 
of diuretics in 2006 (with a later revision in 2010): at that 
point they were not able to include any single trial to the 
systematic revision. Furthermore, in 2011, the Cochrane 
Ear, Nose and Throat Disorders group was able to provide 
recommendations on the use of intra-tympanic steroids or 
gentamicin, based on just one single trial in the former and 
on two studies in the later.
Thus, the limitations of the evidence base for preventive 
strategies of vertigo spells in MD, were a major concern of 
the current study’s authors, and taken into account when 
designing the methodology.
In the study here presented the participants received 
placebo, low dose BH (2×24 mg daily) or high dose BH 
(3×48 mg daily) over nine months. Number of attacks per 
month, duration and severity of vertigo spells, change in 
quality of life scores and different audio-vestibular function 
parameters were the outcome of the study.
Interestingly the incidence of the vertigo spells, after 
treatment, did not differ between the three groups. The 
other results were consistent for all secondary outcomes 
with no significant differences between the placebo, low and 
high dose BH groups.
The study provides a proof to the different types of 
vertigo that patients with MD suffer. We are especially 
interested and concerned in those that occur spontaneously 
without any prior provocative event in particular, 
positioning. As has been previously shown in patients with 
MD, vertigo attacks provoked by a positional change can 
occur and they have a straightforward, non-medical but 
repositioning maneuver, treatment that has shown to be 
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extremely effective (7). In regards to vertigo spells, the 
participants in the study are interestingly homogenous 
for the three arms in terms of activity of the disease as 
the authors required at least the patient to suffer two 
episodes of vertigo per month (spontaneously appearing, 
not positionally provoked) before being included in the 
study. Taking that into account the mean number of 
dizzy spells per month was 5.1 (high dose), 5.8 (low-dose) 
and 6.2 (placebo). This number raises some concern on 
the type of attacks for three reasons. First, because they 
were taken from a one month follow-up in treatment, not 
retrospectively. Second, because of the high numbers which 
indicate that it was a very disabled population. In regards to 
the first question data is used usually prospectively during 
the follow-up of patients however, final adherence to 
established guidelines for the follow-up is usually incorrect 
in up to 50% of published papers (8); as such the evaluation 
with a diary is a probably more robust method not easily 
used (in the timing used by the authors) in other methods of 
treatment (intra-tympanic gentamycin, surgery). Regarding 
the second concern the authors have segregated the number 
of dizzy spells which could be defined as “true MD dizzy 
spell”; and the number is of sufficient nature as to consider 
the patients in a moderate to high severity and results 
significant and to be taken into account.
That defines the fact that patients had to be in an 
active phase of the disease to be included in the study, 
with at least two or more definitive spontaneous episodes 
of vertigo of at least 20 minutes duration. However these 
inclusion criteria could became the underlying cause of a 
selection bias and third concern. The fluctuating nature of 
the disease together with the spontaneous remission rate, 
could somehow explain why all three groups had a similar 
decrease of the vertigo spells rate. The clinical course of 
the disease is cyclical and unpredictable. Actually, there are 
reports which provide data that even without therapeutic 
intervention, the vertigo spells decline along the time as 
vestibular function decreases.
Because the natural history of MD is one of remission 
and recurrence, selecting those patients with an active phase 
of the disease will invariably cause a significant decline 
of the vertigo episodes after the period of the inclusion, 
creating the illusion of a therapeutic efficacy.
The importance of including a placebo controlled 
group is crucial and one of the great pieces of the research, 
but may be insufficient to differentiate the effect of the 
treatment from the cyclical natural history of the disorder. 
Therefore, assessment of the efficacy of treatments for MD 
needs randomized approach, including a control (free of 
treatment) group. Without the former, the placebo effect 
could not be accurately assessed and differentiated from 
spontaneous remission and/or fluctuation of symptoms.
Since there are many observational studies that support a 
beneficial effect of BH on MD, we should raise the question 
whether bias alone can explain the large effects differences 
between observational and experimental studies. Further 
long term randomized, placebo controlled trials should 
be considered to confirm the authors’ findings, and focus 
more specifically on identifying possible predictors for BH 
treatment.
After this paper many questions have been opened 
regarding the evaluation of different modalities of 
treatment for patients with MD. However we have to 
keep in mind that this was not an unexpected result for 
the doctors in charge of these patients. The severity of 
clinical manifestations as measured in the patients included 
in the study (number of dizzy spells and quality of life and 
disability measures) is again a very important point; many 
would consider as an alternative (or even first line) treatment 
the use of intraympanic steroids (9) or gentamicin (10) 
for them in order to provide a transitory or more prolonged 
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